IDH1 and endometrial cancer: We observed that endometrial cancers that developed MPA resistance had significantly increased pT77‐IDH1 positivity (Figure 3h,i), and phosph‐p38 was markedly up‐regulated in MPA‐refractory clinical samples (Figure S3j,k, Supporting Information).